Over the past 18 months the National Institutes of Health has taken multiple steps to get a grip on spiraling Big Data challenges, but the initiatives are still taking shape. And the agency is seeking the input of the genomics, bioinformatics and broader medical communities to help finalize its plans.
In the midst of flat funding for many federal programs as well as last year's across-the-board spending cuts known as sequestration, global health advocacy groups say Congress needs to adopt a long-term budget solution to sustain R&D activities for new drugs, vaccines and other health technologies to combat global health threats.
Years of flat funding from the National Institutes of Health plus across-the-board federal spending cuts known as sequestration could have deleterious effects for cancer research, says a new study by the American Association for Cancer Research.
For several years now, scientists working on an HIV vaccine have been focused on a small set of patients whose immune systems were able to generate rare antibodies able to vanquish most strains of the lethal virus. And over the weekend a team of scientists from South Africa and the U.S. say that one woman--dubbed CAP256-VRC26--may have offered a key to do just that.
The information comes from Genetic Epidemiology Research on Aging (GERA), a cohort of more than 100,000 adults with an average age of 63 years old.
George Washington University and the National Institutes of Health this week took high-speed Internet connections to the next level. The organizations are using their new 100-Gbps links to the Internet2 Network to trial 40-Gbps transfers of genomics data.
The NIH has added a huge amount of medical data--from a diverse group of more than 78,000 people with an average age of 63--to Genetic Epidemiology Research on Aging, one of the nation's largest and most diverse genomics projects.
Sedia Biosciences will use a new $1 million NIH grant to bring forward an HIV diagnostic test it hopes will better assess recently infected individuals and how advanced the virus has become inside the body.
While antiretroviral therapies and preventive measures have helped lessen the impact of HIV, leaders at the National Institutes of Health think a safe, moderately effective vaccine is still needed.
One in three people in the U.S. either already have or are at high risk of developing diabetes, and analyzing genetic data for answers about how best to treat these patients is a daunting task. Now a collection of Big Pharma companies are teaming up to share the burden.